CVS Health (CVS) PT Trimmed to $110 at Credit Suisse
- Wall Street dips as telecoms slump; AmEx surges
- Microsoft (MSFT) Tops Q1 EPS by 8c
- AMD (AMD) Posts Q3 Operating EPS of 3c; Sees Q4 Revenue Down Sequentially
- AT&T (T) Said to Discuss Idea of Takeover in Time Warner (TWX) Meetings
- After-Hours Stock Movers 10/20: (CERC) (ALKS) (PFPT) (MSFT) Higher; (SKX) (RRGB) (AMD) Lower (more...)
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Credit Suisse analyst Robert Willoughby trimmed his price target on CVS Health (NYSE: CVS) to $110.00 (from $115.00) but maintained an Outperform rating after news the US Department of Defense military health program, announced that as of December 1, CVS will no longer be a part of its pharmacy network, replaced by competitor Walgreens.
Willoughby commented, "CVS was on the winning side of a 2011 dispute between Express Scripts and Walgreens that saw Walgreens removed from TRICARE's pharmacy network. The news is consistent with recent efforts by Walgreens to align itself more with payors to gain more pharmacy market share, curbing CVS's opportunity."
The firm is lowering 2017 EPS estimate to $6.55 (from $6.60) on a weaker revenue outlook.
Shares of CVS Health closed at $88.99 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Needham & Company Cuts Price Target on Syntel, Inc. (SYNT) Following Weak 3Q
- Wedbush Cuts Price Target on Genuine Parts (GPC) to $95 Following 3Q
- eBay (EBAY) Turnaround on Track, Buy the Dip - Susquehanna
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS Change, Analyst PT Change
Related EntitiesCredit Suisse, Robert Willoughby
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!